Cns Pharmaceuticals, Inc. · NASDAQ:CNSP
Cns Pharmaceuticals — Investor Presentation (July 2026)
12 slides from Cns Pharmaceuticals's investor presentation, Jul 2, 2026
Slide 1: June 2026 Investor Presentation
June 2026 Investor Presentation
Slide 2: Forward Looking Statements
2 This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business st
Slide 3: Company Highlights
3 Purpose - Built Executive Team Highly experienced executive team with deep expertise in oncology, neurology and rare disease drug development and public company transformation Rapidly Executing a New Corporate Strategy Refocused the company into high - unmet - need in oncology or neurology markets
Slide 4: The CNS Executive Team
4 The CNS Executive Team Rami Levin, MBA President & CEO 30 years of global leadership experience across oncology, CNS, rare diseases, endocrinology, and cell and gene therapy, with a proven track record of scaling organizations, advancing late - stage clinical programs, and driving transformative v
Slide 5: Rapid Execution with Key Building Blocks in Place
5 Rapid Execution with Key Building Blocks in Place Appointed CEO, Rami Levin Commenced pipeline analysis Announced new corporate strategy Closed $22.5 million financing Top Performing PIPE for the First Half of 2026 Appointed CFO, CTO, CMO & CBO Accomplished executive team with specific & relevant
Slide 6: Outcome of Comprehensive Strategic Review
6 Outcome of Comprehensive Strategic Review Independent Analysis Across Clinical, Commercial and Capital Dimensions Underscores Need for a Disciplined Reset Legacy Pipeline Review Strong scientific merit, but GBM focus not aligned with long - term growth strategy Encouraging clinical activity in rec
Slide 7: Disciplined Asset Acquisition Strategy to Unlock Value
7 Disciplined Asset Acquisition Strategy to Unlock Value Clear Selection Criteria Process Capitalizing on Favorable Environment Broad Target Universe Searching Globally • Large Pharma • Biotechnology • Venture - backed assets • Underfunded clinical - stage programs • Shelved/deprioritized assets • D
Slide 8: Focusing on Oncology or Neurology
8 Focusing on Oncology or Neurology Targeting Therapeutic Areas with Proven Investor Interest and Commercial Success, Capitalizing on the Experience of our New Executive Team Oncology Largest and most active sector in biotechnology • Global oncology therapeutics market projected to exceed $400B over
Slide 9: Positioned for Rapid Execution
9 Positioned for Rapid Execution Integrating Diligence & Operational Planning Near Term Inflection Catalyst Cohesive Leadership Team Leveraging functional expertise to drive value Biological Risk Mapping Validate scientific rationale and mechanism of action to ensure best - in - class potential CMC
Slide 10: Why CNSP, Why Now
10 Why CNSP, Why Now. Unique Opportunity to Participate in a Public Biotech Strategic Pivot New Executive Team with Proven Execution Purpose - built executive team with deep expertise across neurology, oncology and rare disease development Strategic Pivot Underway Comprehensive review defining a dis
Slide 11: Clean, Shareholder-Aligned Capital Structure
11 Clean, Shareholder - Aligned Capital Structure May 2026 Private Placement Significantly Enhances Financial Position, Resulting in a Pro Forma Fully Diluted Market Capitalization of ~$50.7 Million Notes Amount Shares As of June 30, 2026¹ 1,461,449 Common stock outstanding $0.001 exercise price; is
Slide 12: Investor Relations: JTC Team
Investor Relations: JTC Team cnsp@jtcir.com
CNS Pharmaceuticals — Investor Presentation (July 2026) on 6ix